Skip to main content
Daniel George, MD, Urology, Durham, NC, Duke Raleigh Hospital

DanielJGeorgeMD

Urology Durham, NC

Professor of Medicine Professor in Surgery Member of the Duke Cancer Institute

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. George's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1992
  • Duke University
    Duke UniversityB.S., 1988

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2014 - 2018
  • NC State Medical License
    NC State Medical License 2003 - 2023
  • MA State Medical License
    MA State Medical License 1998 - 2005
  • MD State Medical License
    MD State Medical License 1995 - 1998

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • George P. Canellos Award for Excellence In Clinical Research 2003
  • Eugene P. Shonfeld Award Kidney Cancer Association, 2002
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Survuval Outcomes of Sipuleucel-T Phase 3 Studies: Impact of Control Arm Cross-over to Salvage Immunotherapy  
    George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG, Cancer Immunol Res, 1/5/2016
  • Clinical Trial Participants with Metastatic Renal Cell Carcinoma Differ From Patients treated in Real-World Practice  
    Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hersch BR, J Oncol Pract, 1/1/2016
  • Trial Design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3  
    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussai..., J Clin Oncol, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
    Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming MT, George DJ, Journal of Clinical Oncology, Genitourinary Cancers Symposium, 1/1/2013
  • Isolation of circulating tumor cells using a novel EMT-based capture method
    Bitting RL, Boominathan R, Rao C, Embree E, George DJ, Connelly MC, Kemeny G, Garcia-Blanco M, Armstrong AJ, Journal of Clinical Oncology, 1/1/2012
  • Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies
    George DJ, Nabhan C, Gomella LG, Whitmore JB, Frohlich MW, Genitourinary Cancers Symposium, General Poster Session B: Prostate Cancer, Journal of Clinical Oncology, 1/1/2011
  • Join now to see all

Lectures

  • Prostate, Colon and smoking cessation 
    Durham, NC - 1/1/2016
  • Extending Survival in Kidney Cancer: The New Reality 
    Chicago, IL - 1/1/2016
  • Duke Cancer Institute’s approach to prostate cancer screening and implementation of an active surveillance program: Doing the right thing for our patients 
    Durham, NC - 1/1/2015
  • Join now to see all

Other

Press Mentions

  • Enzalutamide vs. Abiraterone: Survival, Care Costs Compared
    Enzalutamide vs. Abiraterone: Survival, Care Costs ComparedMay 3rd, 2019
  • Brant Inman, MD, and Smita Nair, PhD, to Test Novel Immunotherapy for Prostate Cancer
    Brant Inman, MD, and Smita Nair, PhD, to Test Novel Immunotherapy for Prostate CancerMarch 2nd, 2016
  • AUA 2019: Survival Rates and Economic Outcomes in Chemotherapy-Naïve Metastatic Castrate Resistant Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide
    AUA 2019: Survival Rates and Economic Outcomes in Chemotherapy-Naïve Metastatic Castrate Resistant Prostate Cancer Patients Treated with Abiraterone Acetate or EnzalutamideMay 3rd, 2019
  • Join now to see all

Hospital Affiliations